Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Anti Epileptic Drugs. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel lacosamide synthesis avoiding toxic reagents. High yield, scalable process for reliable API intermediate supply chain partners.
Discover a novel 4-step synthesis for Brivaracetam API intermediates. This patent-pending route eliminates chiral chromatography, ensuring high purity and cost-effective manufacturing.
Patent CN106432032B reveals a safer PEG-catalyzed route for Levetiracetam manufacturing, ensuring high purity and reduced genotoxic risks for global supply chains.
Patent CN113336726B details a novel synthesis of (R)-3-propyl-γ-butyrolactone using chiral auxiliaries, offering high purity and cost-effective manufacturing for API intermediates.
Patent CN114790151A reveals a cost-effective composite catalytic route for methyl 2-cyano-2-valproate, offering significant supply chain advantages for valproamide manufacturing.
Patent CN103539750A details a novel nano-cuprous oxide catalyzed route for Rufinamide, offering safer room temperature reactions and streamlined purification for reliable API manufacturing.
Patent CN110698379A details a novel levetiracetam preparation method enhancing purity and yield. This report analyzes supply chain advantages and cost reduction in API manufacturing for global procurement teams.
Patent CN102675181B details a solvent-free Levetiracetam synthesis. This report analyzes cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN104725301A offers a cost-effective route for Perampanel intermediates. Enhances supply chain stability and reduces manufacturing complexity significantly.
Patent CN102465159B details a green microbial route for Eslicarbazepine. Enhance supply chain reliability and reduce manufacturing costs with this scalable biocatalytic technology.
Patent CN108715881B reveals a dual-enzyme route for pregabalin intermediates. Achieve 99.5% e.e. and simplified processing for cost-effective API manufacturing.
Patent CN111057735B details a novel esterase route for high-purity chiral intermediates. Discover cost-effective manufacturing and reliable supply chain solutions.
Patent CN112939900A reveals a cost-effective route for Brivaracetam intermediates, eliminating chiral chromatography for scalable pharmaceutical manufacturing.
Patent CN114751849A reveals a novel asymmetric Baeyer-Villiger oxidation route for brivaracetam intermediates, offering superior chiral purity and significant cost reduction in API manufacturing.
Discover the asymmetric transformation method for L-2-aminobutanamide hydrochloride. Enhance purity and reduce costs in levetiracetam manufacturing with our advanced synthesis route.
Patent CN113511994B details a high-purity levetiracetam synthesis using chiral BINOL-derived phosphoric acid, offering superior enantioselectivity and simplified one-pot processing for pharmaceutical manufacturers.
Advanced hydrolysis method for high-purity gabapentin. Reduces toxic impurities and energy consumption. Ideal for API manufacturing scale-up.
Patent CN109593055B details a scalable resolution method for Brivaracetam isomer (2S, 4S), eliminating chromatography for cost-effective pharmaceutical intermediate manufacturing.
Advanced patent CN108658831B reveals a high-yield Pd-catalyzed hydrogenation route for Brivaracetam intermediates, offering significant cost reduction and scalable manufacturing solutions.
Patent CN104496880A details a novel TiCl3-catalyzed synthesis route for Phensuximide intermediates, offering significant cost reduction and supply chain reliability for global pharmaceutical manufacturers.